Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-IM-3050 in Advanced Solid Malignancies
NCT07505771Phase 1Recruiting
- Sponsor
- Immunome
- Start
- Jun 2026
- Primary completion
- Dec 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of 177Lu-IM-3050 in solid tumor (2 arms), sponsored by Immunome. Primary endpoints: Incidence of Treatment-Emergent Adverse Events up to 5 years and Recommended dose of 177Lu-IM-3050 up to 5 years. Started Jun 2026; status: recruiting.
02
Drugs
177Lu-IM-3050
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07505771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07505771.